| "Ten patients with progressive follicular lymphomas (seven with follicular mixed lymphomas, three with follicular, small cleaved cell lymphomas) with clinical indications for systemic therapy received parenteral suramin." | ( Cooper, MR; Kohler, D; La Rocca, RV; Myers, CE; Stein, CA; Uhrich, M; Weinberger, E, 1992) |
| "Thirty-eight patients with follicular lymphoma (age range 29-61 years, median 43) have been treated to date." | ( Arnott, S; Clark, P; Cotter, F; Davis, CL; Dorey, E; Evans, ML; Norton, A; Price, CG; Rohatiner, AZ; Sterlini, J, 1991) |
| "Since June 1985, 121 patients with follicular lymphoma aged 24-61 years (median 43) have received myeloablative therapy (cyclophosphamide: 60 mg/kg x 2, + total body irradiation: 200 cGy x 6) with autologous bone marrow transplantation (CY+TBI+ABMT) as consolidation of 2nd or subsequent remission." | ( Freedman, A; Lim, J; Lister, TA; Nadler, L; Rohatiner, AZ, 1994) |
| "Newly diagnosed follicular lymphoma patients with a low tumor burden (n = 193) were randomly assigned to one of three arms: arm 1, no initial treatment (n = 66); arm 2, prednimustine 200 mg/m2/d for 5 days per month for 18 months (n = 64); or arm 3, interferon alfa 5 MU/d for 3 months then 5 MU three times per week for 15 months (n = 63)." | ( Bastion, Y; Brice, P; Brousse, N; Haïoun, C; Lepage, E; Moreau, P; Solal-Céligny, P; Straetmans, N; Tabah, I; Tilly, H, 1997) |
| "A 34-year-old patient with follicular lymphoma who was treated with CHOP followed by COPP for 3 years, became resistant to treatment in December 1993." | ( Hirayama, Y; Koyama, R; Kuga, T; Matsunaga, T; Nagai, T; Niitsu, Y; Ohta, H; Sakamaki, S, 1997) |
| "Patients with follicular lymphoma (FL) who do not respond to first-line chemotherapy or those who relapse after obtaining a remission have a poor outcome with standard treatment." | ( Brunet, S; Domingo-Albós, A; López, R; Martino, R; Sierra, J; Sureda, A, 1999) |
| "Management of follicular lymphoma after chemotherapy failure has been controversial and has ranged from watchful waiting to high-dose chemotherapy." | ( Blanco, AI; Cabanillas, F; Cox, JD; Ha, CS; Tucker, SL, 1999) |
| "Thirty-three patients with Stage I-III follicular lymphoma were treated with CLI between January 1993 and February 1998." | ( Blanco, AI; Cabanillas, F; Cox, JD; Ha, CS; McLaughlin, P; Tucker, SL; Wilder, RB, 2001) |
| "The best treatment of follicular lymphoma remains to be determined because the long natural history of follicular lymphoma requires mature data for accurate analysis." | ( Avilés, A; Cleto, S; Díaz, N; Díaz-Maqueo, JC; García, EL; Neri, N; Talavera, A, 2001) |
| "Advanced follicular lymphomas, grades I and II, are indolent tumors but are not considered curable with standard therapy." | ( Bard, V; Foon, KA; LaRocca, RV; Rohatgi, N; Sethuraman, G, 2002) |
| "Advanced follicular lymphoma is incurable with conventional chemotherapy and radiotherapy." | ( Braziel, RM; Fisher, RI; Gaynor, ER; LeBlanc, M; Maloney, DG; Miller, TP; Press, OW; Rivkin, SE; Unger, JM, 2003) |
| "Most patients with follicular lymphoma respond to therapy, and the average survival time in large series is approximately 10 years." | ( Armitage, JO; Hoelzer, D; Rummel, MJ; Tobinai, K, 2004) |
| "Advanced-stage follicular lymphoma (FL) and mantle cell lymphoma (MCL) cannot be cured using conventional chemotherapy." | ( Dreyling, M; Hiddemann, W; Lenz, G, 2004) |
| "FND is efficient in treatment of follicular lymphoma." | ( Hofmanová, Z; Klabusay, M; Korístek, Z; Matuska, M; Mayer, J; Muzikárová, M; Navrátil, M; Oborilová, A; Vásová, I; Vinklárková, J, 2004) |
| "Newly diagnosed advanced follicular lymphoma patients (172 patients) were randomly assigned either to an immunochemotherapy regimen (cyclophosphamide, doxorubicin, teniposide, prednisone, and interferon) or to a high-dose therapy followed by purged autologous stem-cell transplantation." | ( Bertrand, P; Colombat, P; Cornillet-LeFebvre, P; Deconinck, E; Delepine, R; Delwail, V; Desablens, B; Escoffre-Barbe, M; Foussard, C; Gressin, R; Jaubert, J; Jenabian, A; Le Pourhiet-Le Mevel, A; Legouffe, E; Maisonneuve, H; Michenet, P; Milpied, N; Ramee, JF; Thyss, A; Travade, P; Vilque, JP, 2005) |
| "A total of 164 patients with follicular lymphoma (grade 1/2), mantle cell lymphoma or lymphoplasmacytic lymphoma (immunocytoma) was randomised to treatment with vincristine 2 mg (day 1) and prednisone 100 mg/m2 (days 1-5) + bendamustine 60 mg/m2 (days 1-5) or + cyclophosphamide 400 mg/m2 (days 1-5) for a total of eight 21-day cycles." | ( Arzberger, H; Boewer, C; Bremer, K; Dachselt, K; Franke, A; Freund, M; Fricke, HJ; Hahnfeld, S; Herold, M; Ismer, B; Klinkenstein, C; Müller, C; Niederwieser, D; Pasold, R; Richter, P; Schirmer, V; Schulze, A; Schulze, M; Schwarzer, A; Weniger, J; Winkelmann, C, 2006) |
| "A 48-year-old male patient with follicular lymphoma, grade II, stage IV, was treated with CHOP, ESHAP and MACOP-B, resulting in partial remission." | ( Chinzei, T; Kawano, S; Kondo, S; Kumagai, S; Okamura, A; Okumachi, Y; Saigo, K; Takenokuchi, M, 2006) |
| "Patients with follicular lymphoma (FL) in advanced stages are currently deemed incurable with standard treatments." | ( Arenillas, L; Balaguer, O; Bosch, F; Campo, E; Colomo, L; Ferrer, A; Giné, E; López-Guillermo, A; Montoto, S; Montserrat, E; Muntañola, A; Plancarte, F; Villamor, N, 2006) |
| "Using this method to follow 14 follicular lymphoma patients treated with autologous stem cell transplantation, molecular markers were successfully defined for 12 patients." | ( Berinstein, NL; Boudreau, A; Buckstein, R; Hewitt, K; Imrie, K; Pennell, N; Reis, M; Seth, A; Spaner, D; Woods, A, 2006) |
| "For patients with follicular lymphoma, the respective OR and CR rates were 100% and 86% as firstline therapy, and 87% and 67% as salvage therapy." | ( Carney, D; Januszewicz, EH; Lin, KI; Prince, HM; Seymour, JF; Tam, CS; Westerman, D; Wolf, M, 2006) |
| "In patients with advanced-stage follicular lymphoma (FL) and mantle cell lymphoma (MCL), conventional chemotherapy remains a noncurative approach, and no major improvement in overall survival has been achieved in recent decades." | ( Dreyling, M; Hiddemann, W; Hoster, E; Lengfelder, E; Nickenig, C; Pfreundschuh, M; Reiser, M; Trumper, L; Unterhalt, M; Wandt, H, 2006) |
| "Advanced follicular lymphoma (FL) is incurable with conventional chemotherapy and radiotherapy, and optimal front-line management is controversial." | ( Braziel, RM; Fisher, RI; Leblanc, M; Maloney, DG; Miller, TP; Press, OW; Unger, JM, 2006) |
| "We report a case of follicular lymphoma in which pulmonary cryptococcosis occurred with cladribine therapy." | ( Kobayashi, M; Mizoroki, F; Nagasaki, E; Nozato, A; Okawa, Y; Shimada, T, 2006) |
| "Treatment strategies for follicular lymphoma have not been established." | ( Akaogi, T; Hayashi, H; Horiike, S; Kimura, S; Kobayashi, Y; Kuroda, J; Matsumoto, Y; Murotani, Y; Nomura, K; Sako, M; Sawai, N; Shimazaki, C; Taniwaki, M; Yoshikawa, T, 2007) |
| "We report here a patient with relapsed follicular lymphoma who developed secondary acute myeloid leukaemia 15 months after radioimmunotherapy (RIT) with (90)Y-ibritumomab tiuxetan, the fifth described case to date." | ( Boni, G; Cecconi, N; Focosi, D; Galimberti, S; Orciuolo, E; Petrini, M, 2008) |
| "A 24-year-old woman was diagnosed with follicular lymphoma in January 1998: she had developed bulky intra-abdominal lymphadenopathy, with repeated relapse and remission by several chemotherapy treatments." | ( Hatta, Y; Ishizuka, H; Kura, Y; Miura, K; Nakagawa, Y; Sawada, U; Takei, K; Takeuchi, J; Yamazaki, T, 2010) |
| "Furthermore, accumulation of MCs in follicular lymphoma (FL) correlates with unfavourable prognosis after immunochemotherapy." | ( Bono, P; Jantunen, E; Karjalainen-Lindsberg, ML; Kosma, VM; Leppä, S; Taskinen, M, 2010) |
| "Patients with follicular lymphoma (FL) typically experience an indolent course; however, the disease is rarely curable with conventional chemotherapy." | ( Bredeson, C; Ewell, M; Goodman, SA; Horowitz, MM; Kahl, BS; Laport, GG; Negrin, RS; Tomblyn, MR; Vose, JM, 2011) |
| "Given the rarity of follicular lymphoma (FL) in children, there is limited data on which to base treatment recommendations." | ( Dogan, A; Galardy, PJ; Khan, SP; Kumar, R; Rodriguez, V, 2011) |
| "Nevertheless, follicular lymphoma remains incurable and characterized by recurrent relapses requiring additional treatment." | ( Cheson, BD, 2011) |
| "Using 3D MRI, B-cell follicular lymphoma growth was quantified in a Pten(+/-)Lkb1(+/hypo) mouse line, before, during and after repeated treatments with a PI3K inhibitor GDC-0941 (75 mg/kg)." | ( Duce, SL; García-Martínez, JM; Wullschleger, S, 2012) |
| "We report a patient with follicular lymphoma who had false positive results on 18-fluorodeoxyglucose positron emission tomography (FDG-PET) tests for more than six months due to inflammatory reactions continuing over a long period of time after chemotherapy with rituximab." | ( Hara, M; Kohashi, S; Miyagawa, M; Miyazaki, Y; Nakase, K; Nawa, Y, 2012) |
| "Treatment of follicular lymphoma with rituximab is currently recommended at a dose of 375 mg/m(2)." | ( Burgstaller, S; Drach, J; Einberger, C; Fridrik, M; Gaiger, A; Greil, R; Heintel, D; Hopfinger, G; Jäger, U; Mannhalter, C; Oberaigner, W; Porpaczy, E; Putman, M; Raderer, M; Skrabs, C; Zeitlinger, M, 2012) |
| "Advanced follicular lymphomas (FL) are considered incurable with conventional chemotherapy and there is no consensus on the best treatment approach." | ( Braziel, RM; Cheson, BD; Czuczman, MS; Dakhil, SR; Fisher, RI; Friedberg, JW; Gopal, AK; Kaminski, M; LeBlanc, M; Maloney, DG; Miller, TP; Press, OW; Rimsza, LM; Spier, C; Unger, JM, 2013) |
| "Long-term follow up of patients with follicular lymphoma treated in the FL2000 study confirms the sustained clinical benefit of rituximab without long-term toxicity." | ( Audhuy, B; Bachy, E; Belhadj, K; Brice, P; Brousse, N; Cartron, G; Delwail, V; Fermé, C; Feugier, P; Foussard, C; Houot, R; Le Gouill, S; Lefort, S; Maisonneuve, H; Morschhauser, F; Salles, G; Sebban, C; Sonet, A, 2013) |
| "As with other indolent lymphomas, follicular lymphoma is felt to be highly treatable, but ultimately incurable." | ( Cheson, BD; Ujjani, C, 2013) |
| "We describe a patient with transformed follicular lymphoma(FL), expressing p53 but remaining in complete remission(CR) due to bendamustine-rituximab(BR)therapy." | ( Abe, T; Arihara, Y; Fujii, S; Fujita, M; Hirako, T; Hoki, T; Jomen, W; Kato, J; Kuroda, H; Maeda, M; Miura, S; Nagashima, K; Okagawa, Y; Sakurai, T; Yamada, M, 2013) |
| "Radiation therapy of follicular lymphoma has showed consistent results, which demonstrated by 100% of 5-year tumor-specific survival in the whole group, 100% disease-free survival in patients with stage II, the lack of recurrence in the irradiation fields." | ( Vinogradova, IuN, 2013) |
| "According to treatment methods, the 56 follicular lymphoma patients were divided into 2 groups: CHOP group (26 cases) and bortezomib group (30 cases)." | ( Li, YL, 2015) |
| "A middle-aged woman with follicular lymphoma being treated with chemotherapy presented with acute onset atraumatic forearm swelling and severe pain." | ( Alolabi, B; El Bahtimi, R; Jenkinson, RJ; Koo, K; Lesieur, M; Smilovici, B, 2015) |
| "Twenty percent of patients with follicular lymphoma (FL) experience progression of disease (POD) within 2 years of initial chemoimmunotherapy." | ( Byrtek, M; Casulo, C; Cerhan, JR; Dawson, KL; Farber, CM; Flowers, CR; Friedberg, JW; Hainsworth, JD; Link, BK; Maurer, MJ; Zelenetz, AD; Zhou, X, 2015) |
| "The optimal initial therapy of follicular lymphoma (FL) remains unclear." | ( Ahmed, M; Cheah, CY; Chihara, D; Davis, RE; Fanale, MA; Fayad, LE; Fowler, NH; Hagemeister, FB; Lee, H; Nastoupil, LJ; Neelapu, SS; Oki, Y; Phansalkar, K; Rodriguez, MA; Romaguera, JE; Samaniego, F; Turturro, F; Wang, ML; Westin, JR, 2016) |
| "A 69-year-old Japanese woman with follicular lymphoma with treatment-related myelodysplastic syndrome was negative for the CD20 antibody at the time of her relapse." | ( Ito, S; Ohigashi, H; Shiratori, S; Teshima, T; Tsutsumi, Y, 2016) |
| "An exploratory analysis of 75 follicular lymphoma patients treated with obinutuzumab or rituximab induction therapy (IT) for 4 weeks in the phase II GAUSS study aimed to determine whether positron emission tomography (PET) results could predict progression-free survival (PFS) and tumor response." | ( Baetz, T; Berge, C; Buckstein, R; Caballero, D; Crump, M; Fine, G; Fingerle-Rowson, G; Gaidano, G; Goy, A; Kostakoglu, L; Martinelli, G; Press, O; Sahin, D; Sehn, L, 2017) |
| "Chemoimmunotherapy in follicular lymphoma is associated with significant toxicity." | ( Bartlett, NL; Blum, KA; Cheson, BD; Czuczman, M; Davids, MS; Jung, SH; Leonard, JP; Levine, E; Lewis, LD; Martin, P; Park, SI; Pitcher, B; Smith, SE; Smith, SM; Ujjani, CS, 2016) |
| "Treatment response of follicular lymphomas (FL) is highly variable." | ( Aulitzky, WE; Dengler, MA; Duppel, J; Horn, H; Ott, G; Rosenwald, A; Staiger, AM; van der Kuip, H; Vöhringer, MC, 2017) |
| "Histological transformation (HT) of follicular lymphoma (FL) to an aggressive lymphoma after chemotherapy remains a key issue." | ( Ansell, SM; Burnette, BL; Colgan, JP; Epperla, N; Habermann, TM; Inwards, DJ; Johnston, PB; Macon, WR; Markovic, SN; Micallef, IN; Nowakowski, GS; Pham, AQ; Porrata, LF; Ristow, KM; Wiseman, GA; Witzig, TE, 2017) |
| "A 63-year-old man with follicular lymphoma was administered standard R-CHOP chemotherapy." | ( Aota, Y; Gotoh, A; Hanyu, N; Honma, T; Kitagawa, N; Komatsu, N; Motoya, K; Nakamura, I; Okuda, Y; Udou, R; Yokoyama, T, 2017) |
| "Most patients with follicular lymphoma (FL) experience multiple relapses necessitating subsequent lines of therapy." | ( Anderson, DM; Ansell, SM; Bartlett, NL; Costello, BA; Fehniger, TA; Gomez, F; Griffith, M; Griffith, OL; Krysiak, K; Kuruvilla, JG; LaPlant, BR; Qi, J; Ramirez, C; Reeder, CB; Siegel, BA; Thye, LS, 2018) |
| "Seventy patients with primary follicular lymphomawere in our hospital were treated with R-CHOP chemotherapy, the ALC/AMC value of peripheral blood was recorded, and the prognosis was assessed by the international prognostic index." | ( Cui, Y; Shi, P, 2018) |
| "The treatment of follicular lymphoma (FL) continues to evolve." | ( Leonard, JP, 2019) |
| "New treatment strategies in follicular lymphoma (FL) are driven by a deeper understanding of microenvironmental cues supporting lymphomagenesis, chemoresistance, and immuno-escape." | ( Morschhauser, F; Ysebaert, L, 2020) |
| "The prognosis and treatment options for follicular lymphoma (FL) remain heterogenous." | ( Gui, L; He, X; Liu, P; Qin, Y; Shi, Y; Yang, J; Yang, S; Zhang, C; Zhou, L; Zhou, S; Zhou, Y, 2021) |
| "Treatment for follicular lymphoma (FL) in the elderly is not well standardized." | ( Baldini, L; Balzarotti, M; Boccomini, C; Bolis, S; Chiarenza, A; Ciccone, G; Corradini, P; Evangelista, A; Ferrero, S; Freilone, R; Ladetto, M; Marina Liberati, A; Nassi, L; Novo, M; Puccini, B; Rattotti, S; Rigacci, L; Rusconi, C; Stelitano, C; Tucci, A; Vitolo, U; Volpetti, S, 2021) |
| "In patients with follicular lymphoma, the prolonged clinical course consisting of multiple relapses is a fundamental challenge that requires clinicians to consider how to best balance treatment efficacy while minimizing toxicity and preserving quality of life." | ( Burke, JM; Leslie, LA; Pagel, JM, 2020) |
| "Endoscopic resection of a follicular lymphoma (FL) presenting as a gastric subepithelial tumor (SET), along with periodic follow up can be a treatment option because gastrointestinal FL cells tend to reside in the primary site, which may explain its indolent nature." | ( Choi, CW; Kim, SJ; Kim, TU, 2021) |
| "Front-line treatment for follicular lymphoma has evolved with the introduction of maintenance therapy, bendamustine (Benda), obinutuzumab (G), and lenalidomide (Len)." | ( Habermann, TM; Maurer, MJ; Nowakowski, GS; Qi, X; Wang, ML; Wang, Y; Witzig, TE; Yang, F; Zhou, S, 2022) |
| "Advanced follicular lymphoma with a high tumor burden has historically been treated with chemoimmunotherapy, but the treatment goal for older patients is relief of symptoms." | ( Miyazaki, K, 2022) |
| "A patient with follicular lymphoma treated with obinutuzumab and bendamustine experienced prolonged coronavirus disease-2019 (COVID-19)." | ( Asakura, S; Saito, T; Ueda, Y; Wada, S; Yano, T, 2022) |
| "Asymptomatic patients with follicular lymphoma (FL) and a low tumour burden can be followed without initial therapy, a strategy called watchful waiting (WW)." | ( Annunziata, S; D'Alò, F; Giordano, A; Hohaus, S; Leccisotti, L; Maccora, D; Maiolo, E; Malafronte, R; Rufini, V, 2023) |
| "Thirty-three patients with follicular lymphoma (FL) (n = 20), marginal zone lymphoma (n = 7), and other iNHL were treated with a median follow-up of 30." | ( Coffey, DG; Cowan, AJ; Fromm, JR; Gooley, TA; Gopal, AK; Graf, SA; Greninger, AL; Libby, EN; Lynch, RC; Rasmussen, H; Shadman, M; Smith, SD; Ujjani, CS; Warren, EH, 2023) |
| "Thirty-three patients with follicular lymphoma (FL) (n = 20), marginal zone lymphoma (n = 7), and other iNHL were treated with a median follow-up of 30." | ( Coffey, DG; Cowan, AJ; Fromm, JR; Gooley, TA; Gopal, AK; Graf, SA; Greninger, AL; Libby, EN; Lynch, RC; Rasmussen, H; Shadman, M; Smith, SD; Ujjani, CS; Warren, EH, 2023) |
| "Thirty-three patients with follicular lymphoma (FL) (n = 20), marginal zone lymphoma (n = 7), and other iNHL were treated with a median follow-up of 30." | ( Coffey, DG; Cowan, AJ; Fromm, JR; Gooley, TA; Gopal, AK; Graf, SA; Greninger, AL; Libby, EN; Lynch, RC; Rasmussen, H; Shadman, M; Smith, SD; Ujjani, CS; Warren, EH, 2023) |